Treatment-naive patients with active relapsing-remitting multiple sclerosis at baseline demonstrate slowing of brain volume loss with alemtuzumab: 5-year outcomes from the CARE-MS I extension study

被引：0
|
作者：
Schippling, S. [1 ]
Rovira, A. [2 ]
Giovannoni, G. [3 ]
Arnold, D. L. [4 ,5 ]
Traboulsee, A. [6 ]
Margolin, D. H. [7 ]
Thangavelu, K. [7 ]
Filippi, M. [8 ]
机构：
[1] Univ Hosp Zurich, Zurich, Switzerland
[2] Vall dHebron Univ Hosp, Barcelona, Spain
[3] Queen Mary Univ London, Barts & London Sch Med, London, England
[4] NeuroRx Res, Montreal, PQ, Canada
[5] Montreal Neurol Inst, Montreal, PQ, Canada
[6] Univ British Columbia, Vancouver, BC, Canada
[7] Sanofi Genzyme, Cambridge, MA USA
[8] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Milan, Italy
来源：
EUROPEAN JOURNAL OF NEUROLOGY | 2016年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P32155
引用
收藏
页码：824 / 825
页数：2
相关论文
共 50 条
  • [1] Treatment-Naive patients with active relapsing-remitting multiple sclerosis at baseline demonstrate continued disability improvement over 5 years with alemtuzumab: the CARE-MS I extension study
    Arroyo Gonzalez, R.
    Dive, D.
    Havrdova, E.
    Hunter, S.
    Margolin, D. H.
    Thangavelu, K.
    Fernandez, O.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 533 - 533
  • [2] Treatment-naive patients with highly active relapsing-remitting multiple sclerosis at baseline demonstrate continued clinical improvement with alemtuzumab over 5 years: CARE-MS I extension study
    Vermersch, P.
    Lycke, J.
    Limmroth, V.
    Singer, B.
    Krieger, S.
    Margolin, D. H.
    Thangavelu, K.
    Berkovich, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2016, 23 : 681 - 681
  • [3] Alemtuzumab improves MRI outcomes in treatment-naive active relapsing-remitting multiple sclerosis patients: three-year follow-up from CARE-MS I
    Arnold, D. L.
    Barkhof, F.
    Cohen, J. A.
    Fox, E. J.
    Selmaj, K. W.
    Margolin, D. H.
    Palmer, J.
    Fisher, E.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 41 - 41
  • [4] Durable efficacy of alemtuzumab on clinical outcomes over 5 years in treatment-naive patients with active relapsing-remitting multiple sclerosis with most patients not receiving treatment for 4 years: CARE-MS I extension study
    Havrdova, E.
    Arnold, D. L.
    Cohen, J. A.
    Compston, D. A. S.
    Fox, E. J.
    Hartung, H. -P.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    Panzara, M. A.
    Coles, A. J.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 45 - 46
  • [5] Durable Effect of Alemtuzumab on Clinical Outcomes Over 5 years in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Despite Most Patients Not Receiving Treatment for 4 Years: CARE-MS I Extension Study
    McCombe, P. A.
    Hartung, H-P
    Havrdova, E.
    Selmaj, K. W.
    Margolin, D. H.
    Kasten, L.
    Compston, D. A. S.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (03) : 406 - 407
  • [6] Improvements in Clinical Outcomes With Alemtuzumab in Treatment-Naive Patients With Active Relapsing-Remitting Multiple Sclerosis Are Durable Over 6 Years in the Absence of Continuous Treatment (CARE-MS I)
    Singer, Barry
    Coles, Alasdair J.
    Boyko, A. Exey N.
    Cohen, Jeffrey A.
    De Seze, Jerome
    Fox, Edward J.
    Havrdova, Eva
    Hartung, Hans-Peter
    Inshasi, Jihad Said
    McCombe, Pamela
    Selmaj, Krzysztof W.
    Vermersch, Patrick
    Van Wijmeersch, Bart
    Margolin, David H.
    Thangavelu, Karthinathan
    Rodriguez, Claudio
    Montalban, Xavier
    NEUROLOGY, 2017, 88
  • [7] Switching from subcutaneous interferon beta-1a to alemtuzumab further decreases new lesion activity and slows brain volume loss in treatment-naive patients with active relapsing-remitting multiple sclerosis: CARE-MS I extension study
    Rovira, A.
    Barkhof, F.
    Kieseier, B.
    Montalban, X.
    Margolin, D. H.
    Thangavelu, K.
    Arnold, D. L.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 560 - 561
  • [8] Relapse Outcomes with Alemtuzumab vs. Rebif® in Treatment-Naive Relapsing-Remitting Multiple Sclerosis (CARE-MS I): Secondary and Tertiary Endpoints
    Fox, Edward
    Arnold, Douglas
    Brinar, Vesna
    Cohen, Jeffrey
    Coles, Alasdair
    Confavreux, Christian
    Giovannoni, Gavin
    Hartung, Hans
    Havrdova, Eva
    Selmaj, Krzysztof
    Stojanovic, Miroslav
    Weiner, Howard
    Lake, Stephen
    Margolin, David
    Panzara, Michael
    Compston, Alastair
    NEUROLOGY, 2012, 78
  • [9] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    EUROPEAN JOURNAL OF NEUROLOGY, 2014, 21 : 683 - 683
  • [10] Durable reduction of disability with alemtuzumab in treatment-naive relapsing-remitting multiple sclerosis patients: 3-year follow-up of the CARE-MS I study
    Wiendl, H.
    Palmer, J.
    Margolin, D. H.
    JOURNAL OF NEUROLOGY, 2014, 261 : S442 - S443
12345